Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bank of America Securities Reaffirms Their Buy Rating on Neurocrine (NBIX)

Tipranks - Tipranks - Wed Jan 28, 7:28AM CST

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Neurocrine, with a price target of $191.00.

Claim 50% Off TipRanks Premium

Ahmad covers the Healthcare sector, focusing on stocks such as Neurocrine, Ascendis Pharma, and Rhythm Pharmaceuticals. According to TipRanks, Ahmad has an average return of 2.6% and a 52.93% success rate on recommended stocks.

In addition to Bank of America Securities, Neurocrine also received a Buy from Truist Financial’s Danielle Brill in a report issued yesterday. However, on the same day, Morgan Stanley maintained a Hold rating on Neurocrine (NASDAQ: NBIX).

See the top stocks recommended by analysts >>

Based on Neurocrine’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $794.9 million and a net profit of $209.5 million. In comparison, last year the company earned a revenue of $622.1 million and had a net profit of $129.8 million

Read More on NBIX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).